Clinical Trial Update: Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating efficacy and safety when switching from candesartan 32 mg to a fixed-dose olmesartan 40 mg/amlodipine 10 mg combination in hypertension…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Candesartan (candesartan)
• Olmesartan/Amlodipine fixed-dose combination (olmesartan/amlodipine)

Snippet

Sponsor: Institut für Pharmakologie und Präventive Medizin | Conditions: Hypertension | Phase 4 | Status: COMPLETED